U.S. FDA Requests Halt To CytRx Trial Of Lou Gehrig’s Disease Drug (India)
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has asked India's CytRx to stop its Phase II trial of a Lou Gehrig-disease drug because the company lacks the data to continue. The U.S. agency asked the company for more analysis of toxicology studies performed on animals for the arimoclomol drug aimed at treating amyotropic lateral sclerosis. CytRx said there was no data in any of the trials related to safety in humans, and the firm has asked for clarification. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.